Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"NMD PHARMA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NMD Pharma Initiates a Combined Phase I\/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"DENMARK","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"NMD PHARMA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NMD Pharma Doses the First Myasthenia Gravis Patient in a Combined Phase I\/IIa Clinical Trial of NMD670","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"DENMARK","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"NMD PHARMA","sponsor":"Jeito Capital","pharmaFlowCategory":"D","amount":"$39.6 million","upfrontCash":"Undisclosed","newsHeadline":"NMD Pharma Raises \u20ac35 Million in a New Financing","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"DENMARK","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"NMD PHARMA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NMD Pharma Reports Positive Top-Line Data from a Phase I\/IIa Clinical Trial of NMD670 in Patients with Myasthenia Gravis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"DENMARK","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"NMD PHARMA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NMD Pharma Receives IND Clearance to Start a Phase II Clinical Trial of NMD670 for the Treatment of Symptoms of Spinal Muscular Atrophy Type 3","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"DENMARK","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling"},{"orgOrder":0,"company":"NMD PHARMA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NMD Pharma Initiates Phase I Safety, Tolerability and Pharmacokinetics Study of NMD1343","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"DENMARK","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I"},{"orgOrder":0,"company":"NMD PHARMA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NMD Pharma initiates Phase II trial of NMD670 in Spinal Muscular Atrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"DENMARK","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II"},{"orgOrder":0,"company":"NMD PHARMA","sponsor":"Novo Holdings","pharmaFlowCategory":"D","amount":"$80.0 million","upfrontCash":"Undisclosed","newsHeadline":"NMD Pharma Raises \u20ac75 Million (~$80 million) in a Series B Financing","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"DENMARK","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II"},{"orgOrder":0,"company":"NMD PHARMA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NMD Pharma Receives FDA IND Clearance to Initiate a Phase 2b Clinical Trial of NMD670 in Generalized Myasthenia Gravis Patients in the US","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"DENMARK","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I"}]

    Find Clinical Drug Pipeline Developments & Deals by NMD PHARMA

    Menu

    NMD PHARMA

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              NMD PHARMA

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Denmark
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              NMD Pharma Receives FDA IND Clearance to Initiate a Phase 2b Clinical Trial of NMD670 in Generalized Myasthenia Gravis Patients in the US

              Details:

              NMD670 is a first-in-class, muscle-targeted small molecule inhibitor of the skeletal muscle specific ClC-1 chloride ion channel. It is being evaluated for the treatment of patients with generalized myasthenia gravis (gMG) who are AChR or MuSK antibody positive.

              Lead Product(s): NMD670

              Therapeutic Area: Immunology Product Name: NMD670

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 22, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              NMD PHARMA

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Denmark
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              NMD Pharma Raises €75 Million (~$80 million) in a Series B Financing

              Details:

              The proceeds will be used to complete three Phase 2 clinical studies of first-in-class ClC-1 molecule inhibitor NMD670 in myasthenia gravis, spinal muscular atrophy and Charcot-Marie-Tooth disease.

              Lead Product(s): NMD670

              Therapeutic Area: Genetic Disease Product Name: NMD670

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Novo Holdings

              Deal Size: $80.0 million Upfront Cash: Undisclosed

              Deal Type: Series B Financing November 15, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              NMD PHARMA

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Denmark
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              NMD Pharma initiates Phase II trial of NMD670 in Spinal Muscular Atrophy

              Details:

              NMD670 is a first-in-class small molecule inhibitor of the muscle-specific chloride ion channel, the ClC-1 ion channel, which is investigated for the treatmet of spinal muscular atrophy.

              Lead Product(s): NMD670

              Therapeutic Area: Genetic Disease Product Name: NMD670

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 26, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              NMD PHARMA

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Denmark
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              NMD Pharma Initiates Phase I Safety, Tolerability and Pharmacokinetics Study of NMD1343

              Details:

              NMD1343 is a novel small molecule inhibitor of the muscle-specific chloride ion channel, the ClC-1 ion channel, and NMD Pharma’s second clinical development candidate

              Lead Product(s): NMD1343

              Therapeutic Area: Neurology Product Name: NMD1343

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 23, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              NMD PHARMA

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Denmark
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              NMD Pharma Receives IND Clearance to Start a Phase II Clinical Trial of NMD670 for the Treatment of Symptoms of Spinal Muscular Atrophy Type 3

              Details:

              NMD670 is a first-in-class small molecule inhibitor of the muscle specific chloride ion channel, the ClC-1 ion channel. NMD Pharma has pre-clinically demonstrated that ClC-1 inhibition can enhance neuromuscular transmission and ultimately skeletal muscle function.

              Lead Product(s): NMD670

              Therapeutic Area: Genetic Disease Product Name: NMD670

              Highest Development Status: IND Enabling Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable December 14, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              NMD PHARMA

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Denmark
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              NMD Pharma Reports Positive Top-Line Data from a Phase I/IIa Clinical Trial of NMD670 in Patients with Myasthenia Gravis

              Details:

              NMD670, a small molecule inhibitor of skeletal muscle-specific ClC-1, Administration of single doses of NMD670 was associated with clinically significant improvements in Quantitative Myasthenia Gravis Score with up to 50% of patients meeting pre-specified responder criterion.

              Lead Product(s): NMD670

              Therapeutic Area: Immunology Product Name: NMD670

              Highest Development Status: Phase I/ Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 11, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              NMD PHARMA

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Denmark
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              NMD Pharma Raises €35 Million in a New Financing

              Details:

              Proceeds from the financing will be used to support the company as it progresses its lead candidate, NMD670, through completion of the ongoing Phase 2a proof-of-concept trial in patients with Myasthenia Gravis (MG).

              Lead Product(s): NMD670

              Therapeutic Area: Immunology Product Name: NMD670

              Highest Development Status: Phase I/ Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Jeito Capital

              Deal Size: $39.6 million Upfront Cash: Undisclosed

              Deal Type: Financing February 15, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              NMD PHARMA

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Denmark
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              NMD Pharma Doses the First Myasthenia Gravis Patient in a Combined Phase I/IIa Clinical Trial of NMD670

              Details:

              NMD670 is in development to treat the symptoms of MG and is also being evaluated for the treatment of other neuromuscular diseases.

              Lead Product(s): NMD670

              Therapeutic Area: Immunology Product Name: NMD670

              Highest Development Status: Phase I/ Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 30, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              NMD PHARMA

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Denmark
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              NMD Pharma Initiates a Combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis

              Details:

              NMD670 is a first-in-class small molecule inhibitor of the muscle specific chloride ion channel, the ClC-1 ion channel.

              Lead Product(s): NMD670

              Therapeutic Area: Immunology Product Name: NMD670

              Highest Development Status: Phase I/ Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 06, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
              Aspen API. More than just an API.
              Post Enquiry
              POST ENQUIRY